Regulus Therapeutics | RGLS - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
AstraZeneca USD 3.91B 1.28B 2026-03
Biogen USD 377.7M 433.7M 2026-03
Celldex Therapeutics USD -81.32M 14.27M 2025-12
Cipla INR 11.69B 6.85B 2025-12
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD 56.84M 63.78M 2025-12
CSL USD 2.61B 1.21B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Grifols EUR 257.85M 190.87M 2024-12
Immunic USD -19.3M 6.28M 2025-12
Incyte USD 343.6M 46.34M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -93M 135M 2026-03
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
Merck USD 3.42B 3.32B 2025-12
Omeros USD -65.12M 21.27M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 6.23B 2025-12
Takeda JPY 133.86B 105.69B 2025-12